MCB-613 exploits a collateral sensitivity in drug resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

Targeted therapies have revolutionized cancer chemotherapy. Unfortunately, most patients develop multifocal resistance to these drugs within a matter of months. Here, we used a high-throughput phenotypic small molecule screen to identify MCB-613 as a compound that selectively targets EGFR-mutant, EG...

Descripción completa

Detalles Bibliográficos
Autores principales: Bassil, Christopher F., Anderson, Gray R., Mayro, Benjamin, Askin, Kayleigh N., Winter, Peter S., Gruber, Samuel, Hall, Tierney M., Hoj, Jacob P., Cerda-Smith, Christian, Hutchinson, Haley M., Killarney, Shane T., Singleton, Katherine R., Qin, Li, Jubien-Girard, Kévin, Favreau, Cécile, Martin, Anthony R., Robert, Guillaume, Benhida, Rachid, Auberger, Patrick, Pendergast, Ann Marie, Lonard, David M., Puissant, Alexandre, Wood, Kris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882253/
https://www.ncbi.nlm.nih.gov/pubmed/36711936
http://dx.doi.org/10.1101/2023.01.17.524094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9882253/
https://www.ncbi.nlm.nih.gov/pubmed/36711936
http://dx.doi.org/10.1101/2023.01.17.524094

Ejemplares similares